Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) with Anti-Angiogenesis and Chemotherapy in Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Protocol No
HCRN-GI18-333-SEQUEL
Staff Member
Ben George
Phase
II
Summary

This study is being done to see what is the most effective way of giving chemotherapy (specifically Paclitaxel) when it is given with Pembrolizumab and Ramucirumab (giving it continuously or giving breaks).

Pembrolizumab, Ramucirumab, and Paclitaxel are approved by the FDA for the treatment of your type of cancer, but their use as the treatment regimen in this study is investigational.

We don't know if this study will help you. Your condition may get better, but it could stay the same or even get worse. We hope the information from this study will help us develop a better treatment for stomach cancer in the future.
Objective
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer, Other Gastrointestinal, Esophagus, Gastrointestinal Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT04069273